New CAR-T therapy aims to calm overactive immune system in muscle weakness disease
NCT ID NCT07556120
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses the body's own immune cells to target and reduce harmful immune activity. The main goal is to check safety and see how well the body tolerates it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at debilitating muscle weakness
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
- New drug trial aims to ease muscle weakness in rare disease
- New shot could ease daily struggles for myasthenia gravis patients
- New study lets myasthenia gravis patients rate their own symptoms on a new drug